4-Star Stocks Poised to Pop: Allergan

Before you go, we thought you'd like these...
Before you go close icon

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, multi-specialty health care company Allergan (NYS: AGN) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Allergan's business and see what CAPS investors are saying about the stock right now.

Allergan facts

Headquarters (founded)Irvine, Calif. (1948)
Market Cap$29.0 billion
IndustryPharmaceuticals
Trailing-12-Month Revenue$5.4 billion
ManagementChairman/CEO David Pyott
CFO Jeffrey Edwards
Return on Equity (average, past 3 years)10.9%
Cash/Debt$2.6 billion / $1.6 billion
Dividend Yield0.2%
CompetitorsBausch & Lomb
Johnson & Johnson
Novartis

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 94% of the 415 members who have rated Allergan believe the stock will outperform the S&P 500 going forward.  

Just last month, one of those Fools, All-Star ikkyu2, succinctly summed up the bull case for our community:

BoTox is a verb and is the only FDA-approved treatment for chronic migraine, which is maybe the #2 or #3 contributor of lost work days in the country. And it actually works. I don't think Allergan can help but grow earnings from here.

If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future. Of course, despite a strong four-star rating, Allergan may not be your top choice.

We've found another stock we are incredibly excited about -- excited enough to dub it "The Motley Fool's Top Stock for 2012." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.

Want to see how well (or not so well) the stocks in this series are performing? Follow the newTrackPoisedToCAPS account.

At the time this article was published Fool contributor Brian Pacampara owns no position in any of the companies mentioned. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services have recommended buying shares of Novartis and Johnson & Johnson. Motley Fool newsletter services have recommended creating a diagonal call position in Johnson & Johnson. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners